Medical Innovation for Enhanced Patient Care

Founded in June 2018, Avicenna.AI was formed through a collaboration between Cyril Di Grandi, a software and medical device expert and Peter Chang, MD, a radiologist and AI expert.

Avicenna.AI secured its initial capital infusion of $2.7 million through investments from the French companies Innovacom and CEMAG Invest.

Avicenna.AI introduced its first products, CINA-ICH and CINA-LVO, triage tools for stroke detection. Both solutions obtained the CE-marking in March, swiftly followed by FDA clearance in June.

Avicenna.AI introduced CINA-PE and CINA-AD, two solutions designed for Pulmonary Embolism and Aortic Dissection detection. These innovations achieved CE-marking in December.

In May 2021, Avicenna.AI successfully obtained FDA clearance for CINA-PE and CINA-AD, while also launching and securing the CE marking for its new Stroke quantification tool, CINA-ASPECTS.

Avicenna.AI secured a Series A funding round, bringing aggregated investment close to $10 million. The round was backed by existing investors Innovacom and CEMAG Invest.

Avicenna.AI introduced its new Incidental findings Suite, with the launch of CINA-iPE for unsuspected Pulmonary Embolism detection.

Avicenna.AI Secures Two FDA Clearances For Stroke Assessment And Opportunistic Pulmonary Embolism.

Avicenna.AI Secures a new FDA Clearance For Incidental Vertebral Compression fracture Detection.

Avicenna.AI Secures a new FDA Clearance For Cervical Spine Fracture detection.

CINA-CSpine is now CE Marked. A new product for Vertebral Compression Fracture Assessment, CINA-VCF Quantix is launched in Europe.

Avicenna.AI has launched AVI, a new platform that delivers AI results seamlessly into healthcare ecosystems.